COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

Source: 
Fierce Biotech
snippet: 

Genfit has told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis (NASH) data. The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.